Novo Nordisk has announced a major pricing shift for its diabetes drug Ozempic, offering it directly to U.S. patients without insurance for $499 per month. The new out-of-pocket price cuts the drug’s list cost by more than 50 percent and is now available through the company’s digital platform NovoCare, along with select telehealth providers including GoodRx, Ro, and LifeMD. The move is designed to improve access to Ozempic for millions of Americans living with Type 2 diabetes who lack insurance coverage.
By circumventing pharmacy benefit managers and other intermediaries, the Danish drugmaker aims to simplify the purchasing process and reduce the financial burden on patients who typically face much higher retail prices at traditional pharmacies. Ozempic, which contains the active ingredient semaglutide, has gained widespread attention not only for managing blood sugar but also for its weight loss effects. Although it is approved by the U.S. Food and Drug Administration (FDA) to treat Type 2 diabetes, demand has surged among patients and providers seeking alternatives to more expensive obesity medications.
Novo Nordisk’s obesity drug Wegovy, also based on semaglutide, has faced persistent supply shortages since its launch. The company said the new $499 price point was intentionally aligned with the list price of Wegovy to prevent patients from switching between the two medications based on affordability alone. By offering a consistent price for both treatments, Novo Nordisk hopes to stabilize patient usage patterns and reduce off-label prescribing.
Ozempic made more accessible for uninsured Americans
Dave Moore, Novo Nordisk’s Executive Vice President for the U.S. market, said the initiative is part of a broader effort to expand patient access and respond to affordability concerns that have dominated recent healthcare debates. The company also indicated that this direct model could serve as a foundation for future drug launches, particularly as it looks to strengthen its position in the growing GLP-1 market.
The announcement comes at a time of mounting pressure on drug manufacturers to lower costs. U.S. lawmakers and regulators are increasingly focused on drug pricing reform, particularly as Medicare prepares to negotiate directly with manufacturers on high-cost medications starting in 2027 under the Inflation Reduction Act. By introducing a direct-pay option ahead of these regulatory shifts, Novo Nordisk is positioning itself as a proactive player in the evolving pricing landscape.
Lawmakers eye pharma pricing reform amid Medicare talks
Telehealth platform GoodRx, one of the program’s launch partners, will offer access to Ozempic at the discounted rate through a network of approximately 70,000 pharmacies across the United States. The collaboration highlights a growing trend among pharmaceutical companies to partner with digital healthcare providers in delivering cost-controlled therapies directly to patients. The market responded favorably to the announcement, with Novo Nordisk shares rising as much as five percent.
Analysts noted that the pricing move is unlikely to erode revenues significantly due to the relatively small proportion of uninsured patients, while potentially expanding the company’s reach in a competitive and high-growth therapeutic category. Novo Nordisk’s direct-to-consumer pricing model marks a notable shift in how specialty drugs may be distributed in the U.S. Moving beyond the traditional insurance framework, the company is testing a strategy that could reshape access to essential treatments and set a precedent for broader pharmaceutical pricing reforms. – By Content Syndication Services.